# CURRENT_OPERATIONAL.md — Knee-OA independent review ready

> **STATUS:** PRODUCT-OWNER FUNCTIONAL/DESIGN ACCEPTANCE RECORDED / INDEPENDENT MULTI-AXIS REVIEW PACKET READY.
> **Updated:** 2026-09-11 Asia/Nicosia.
> **Canonical home:** `athpapachr-cmd/osteoporosis`.
> **Verified main:** `d9f312f6d2d596ec0bd4f35f6de56ad98dc34b37`.
> **Pinned accepted candidate branch/head:** `feat/physio-referral-knee-oa-prototype-v1-2026-09-11` @ `6539351c592c1dc3e49931057b63925dea3cb94d`.
> **Tested substantive implementation head:** `243095ca9545bd2f96be8986520aeae8c3551c27`.
> **Review branch:** `review/physio-referral-knee-oa-independent-v1-2026-09-11`.
> **ACTIVE RUNTIME / DESIGN / CANONICAL WRITER:** NONE; review-preparation writer released.
> **PR / merge / deploy / production smoke authority:** NONE.
> **Real-patient use / production integration:** NOT AUTHORIZED.

## 1. Product-owner acceptance

The product owner reviewed the refined Knee-OA prototype direction and explicitly stated that the design is liked and authorized progression. This records product-owner design/functional-direction acceptance of the pinned candidate.

This is **not** clinical validation, accessibility validation, commercial validation, source-to-claim validation or release authority.

## 2. Independent review packet now ready

The exact review artifacts are:

```text
clinic_utilities/physio_referral_product/KNEE_OA_INDEPENDENT_REVIEW_PACKET_V1.md
clinic_utilities/physio_referral_product/KNEE_OA_INDEPENDENT_REVIEW_PROMPT_V1.md
```

The packet forces separate review of:

```text
clinical / evidence integrity
physiotherapy usefulness / professional autonomy
UX / accessibility / cognitive load
commercial differentiation / recurring value / willingness to pay
```

It also requires a distinct source-to-claim integrity audit for material evidence claims.

## 3. Exact next action

Run the independent review against the pinned candidate. The reviewer must not inherit prior PASS conclusions and must classify every finding as:

```text
BLOCKER
MATERIAL BEFORE SECOND DIAGNOSIS
MATERIAL BEFORE COMMERCIAL PILOT
IMPROVEMENT
LATER / OPTIONAL
```

The reviewer must explicitly identify what should be **removed**, not only what should be added.

No implementation changes are authorized during the review itself. Findings return to the product owner for disposition first.

## 4. HOLD

No new diagnosis, feature expansion, production CU-1 rewrite, public hosting, auth/billing, merge or deployment before the independent-review findings are reviewed and prioritized.
